BioSpace News Archive

Deals

Watch Out: Gilead is Not Done Shopping

Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.

January 10, 2018
·
3 min read
·
Mark Terry
Business

Noxilizer Leaves Baltimore BioPark for New Arundel HQ

The company inked a lease for 10,481 square feet of office space located off of Route 100 in Hanover.

January 10, 2018
·
1 min read
Deals

Nestle Emerges as the Frontrunner for Merck KGaA’s $5B Consumer Health Biz

Nestle submitted the highest offer and Merck was likely to select a winner during the first quarter, but might also choose not to sell the assets after all.

January 10, 2018
·
1 min read
Deals

Fosun Pays $18M for China Rights to Novel Parkinson’s Disease Drug

Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.

January 10, 2018
·
1 min read
Business

GlaxoSmithKline CEO Replaced 50 Top Managers, Lured Execs From Google, Novartis and Teva

GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.

January 10, 2018
·
2 min read
·
Alex Keown
7 Key Products That Could Help Dig Valeant Out of Its Hole

Valeant’s CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.

January 10, 2018
·
1 min read
Deals

GlaxoSmithKline is Eyeing Pfizer’s $15B+ Consumer Biz

GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.

January 10, 2018
·
2 min read
·
Alex Keown
New Venture Fund Banks $102M for Biotech and Medical Device Development

Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that focuses on supporting start-ups in in life sciences and IT.

January 10, 2018
·
3 min read
Policy

3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China

3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.

January 10, 2018
·
1 min read
Drug Development

Why Diffusion Pharma Surged After Its Biotech Showcase Presentation

Shares of Diffusion Pharma shot up more than 40 percent Tuesday after the company provided an overview of the company and its Phase III candidate.

January 10, 2018
·
2 min read
·
Alex Keown